...
机译:Carboplatin-PAClitaxel的随机期II试验与晚期(IIII-IV)或经复制的子宫浆液癌的Carboplatin-PACLitaxel-Trastuzumab(NCT01367002):更新总存活分析
John Hopkins School of Medicine;
University of Maryland;
University of Arkansas for Medical Sciences;
Yale University;
University of Arizona;
Duke University School of Medicine;
The Ohio State University School of Medicine;
Albert Einstein College/Montefiore Medical Center;
John Muir Medical Center;
Penrose Cancer Center-St. Francis;
Walter Reed Medical Center;
Hackensack Meridian Health Neptune;
Greater Baltimore Medical Center;
Stanford Women's Cancer Center;
The Ohio State University School of Medicine;
The Ohio State University School of Medicine;
Duke University School of Medicine;
Duke University School of Medicine;
University of Arizona;
University of Arkansas for Medical Sciences;
John Hopkins School of Medicine;
Hackensack Meridian Health Neptune;
Duke University School of Medicine;
Hackensack Meridian Health Neptune;
机译:Carboplatin-PAClitaxel的随机期II试验与晚期(IIII-IV)或经复制的子宫浆液癌的Carboplatin-PACLitaxel-Trastuzumab(NCT01367002):更新总存活分析
机译:每周剂量密集的紫杉醇和卡铂与常规紫杉醇和卡铂作II-IV期卵巢癌一线治疗的随机III期试验的生活质量结果:日本妇科肿瘤学小组试验(JGOG3016)。
机译:常规紫杉醇和卡铂的随机期II / III试验,或没有贝伐单抗与剂量 - 致密紫杉醇和卡铂,在IVB期间,复发或持续的宫颈癌:日本临床肿瘤组研究(JCOG1311)
机译:在两个阶段的III期随机临床试验中比较评估生存概率的方法。
机译:曲妥珠单抗和紫杉醇方案联合卡铂或表柔比星作为新辅助疗法对临床II-III期HER2阳性乳腺癌患者的疗效和安全性分析:第2期开放标签多中心随机试验
机译:任随时性,第一线FiguTumumab与PACLITAXEL和CARBOPOLATIN与PACLITAXEL和CARBOPOLATIN联合的患者,单独的非小细胞肺癌患者